Patents by Inventor Victor D. Fedorov

Victor D. Fedorov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY
    Publication number: 20220162340
    Abstract: The present invention provides immunoresponsive cells, including T cells, cytotoxic T cells, regulatory T cells, and Natural Killer (NK) cells, expressing an antigen recognizing receptor and an inhibitory chimeric antigen receptor (iCAR). Methods of using the immunoresponsive cell include those for the treatment of neoplasia and other pathologies where an increase in an antigen-specific immune response is desired.
    Type: Application
    Filed: January 24, 2022
    Publication date: May 26, 2022
    Applicant: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Victor D. Fedorov, Michel Sadelain
  • Compositions and methods for immunotherapy
    Patent number: 11267901
    Abstract: The present invention provides immunoresponsive cells, including T cells, cytotoxic T cells, regulatory T cells, and Natural Killer (NK) cells, expressing an antigen recognizing receptor and an inhibitory chimeric antigen receptor (iCAR). Methods of using the immunoresponsive cell include those for the treatment of neoplasia and other pathologies where an increase in an antigen-specific immune response is desired.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: March 8, 2022
    Assignee: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Victor D. Fedorov, Michel Sadelain
  • COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY
    Publication number: 20150376296
    Abstract: The present invention provides immunoresponsive cells, including T cells, cytotoxic T cells, regulatory T cells, and Natural Killer (NK) cells, expressing an antigen recognizing receptor and an inhibitory chimeric antigen receptor (iCAR). Methods of using the immunoresponsive cell include those for the treatment of neoplasia and other pathologies where an increase in an antigen-specific immune response is desired.
    Type: Application
    Filed: September 11, 2015
    Publication date: December 31, 2015
    Inventors: Victor D. Fedorov, Michel Sadelain